RTI Surgical Holdings Inc

RTI Surgical — Regeneration Technologies — Roth Growth Stock Conference (February 2008)

30 slides from RTI Surgical's conference presentation, Feb 19, 2008

  1. Slide 1: Rule 425 filing legend and forward-looking statements

    Slide 1: Rule 425 filing legend and forward-looking statements

    Filed by Regeneration Technologies, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-6 under the Securities Exchange Act of 1934 Subject Company: Regeneration Technologies, Inc. Commission File No.:333-148305 Forward Looking Statements This communicati

  2. Slide 2: Roth Growth Stock Conference

    Slide 2: Roth Growth Stock Conference

    Roth Growth Stock Conference Brian K. Hutchison Chairman, President and CEO

  3. Slide 3: Forward Looking Statement

    Slide 3: Forward Looking Statement

    FORWARD LOOKING STATEMENT The Private Securities Litigation Reform Act of 1995 provides a “safe harbor” for certain forward-looking statements. The forward-looking statements contained in this document are subject to certain risks and uncertainties, such as our ability to maintain our existing strat

  4. Slide 4: More Information

    Slide 4: More Information

    MORE INFORMATION The proposed merger will be submitted to the respective stockholders of Regeneration Technologies and Tutogen for their consideration, and Regeneration Technologies and Tutogen have filed a registration statement, a joint proxy statement/prospectus and other relevant documents conce

  5. Slide 5: Merger Announcement

    Slide 5: Merger Announcement

    MERGER ANNOUNCEMENT On November 13, 2007, Regeneration Technologies, Inc. and Tutogen Medical, Inc. announced a merger to create the leading provider of sterile biologic solutions for patients around the world, reaching a broad range of markets and medical specialties with a diversified mix of impla

  6. Slide 6: About the Transaction

    Slide 6: About the Transaction

    ABOUT THE TRANSACTION Terms of the deal: • Tax-free, stock-for-stock exchange • Tutogen shareholders will receive 1.22 shares of newly issued RTI common stock in exchange for each share of Tutogen common stock they own • Expect to close in Q1 2008, subject to regulatory and other customary condition

  7. Slide 7: Combined Leadership

    Slide 7: Combined Leadership

    COMBINED LEADERSHIP Executive Leadership: • Brian Hutchison, Chairman and CEO • Guy Mayer, President – focused on international activities and sales and marketing • Tom Rose, VP, CFO and Secretary • Bob Johnston, VP Finance Board of Directors: • Total of 12 directors – Seven directors from RTI board

  8. Slide 8: Significant Market Opportunity Expansion

    Slide 8: Significant Market Opportunity Expansion

    SIGNIFICANT MARKET OPPORTUNITY EXPANSION Both companies are aligned with the increasing trends of biologic devices Regeneration Biologics Tutogen* Technologies SPORTS HIPS/ CRANIO- HERNIA SURGICAL SPINE DENTAL DENTAL SPINE MEDICINE KNEES MAXILLOFACIAL REPAIR SPECIALTY $1.5 billion addressable market

  9. Slide 9: Cornering the Market

    Slide 9: Cornering the Market

    CORNERING THE MARKET • BioCleanse • Exclusive supply source • Tutoplast • Supported by clinical studies • Highest safety profiles • Significant margin expansion Allograft: Tissue Xenograft Human Recovery Processing Animal Recovery • Well defined market • Increased tissue supply • Steady demand • Pre

  10. Slide 10: Implant Segments

    Slide 10: Implant Segments

    IMPLANT SEGMENTS Int'l Other 6% 26% Surgical Spec Other BGS 5% 6% RTI Spine 10% 43% Spine Sports Int'l 32% Med 14% 25% Other 14% Dental Sports Int'l 17% Med 28% Spine 16% 10% Combined Tutogen Company Dental 48%

  11. Slide 11: Combined Implant Segments

    Slide 11: Combined Implant Segments

    COMBINED IMPLANT SEGMENTS RTI Tutogen Combined Spine Sports Medicine Bone Graft Substitutes General Orthopedic Other Dental Urology Hernia Ophthalmology Breast Reconstruction ENT International

  12. Slide 12: Key Distributors

    Slide 12: Key Distributors

    KEY DISTRIBUTORS Significantly reducing dependency on single distributors RTI Int'l Tutogen 6% Other 14% Int'l Other 28% 34% MSD 60% ZMH 58% Combined Company ZMH Int'l 22% 14% MSD Other 37% 27%

  13. Slide 13: Positive Trends for Both Companies

    Slide 13: Positive Trends for Both Companies

    POSITIVE TRENDS FOR BOTH COMPANIES Pro Forma Combined Company Revenues Q1 Q2 Q3 Q4 Total Calendar Year $ in thousands 2007 $35,032 $37,086 $38,944 $40,456 $151,518 2006 $27,540 $28,343 $28,909 $30,554 $115,346 Y/Y $ increase $7,492 $8,743 $10,035 $9,902 $36,172 Y/Y Growth 27.2% 30.8% 34.7% 32.4% 31.

  14. Slide 14: Who We Are

    Slide 14: Who We Are

    WHO WE ARE Began operations in 1998 – University of Florida technology transfer Leading provider of biologic tissue repair implants for the orthopedic industry Our portfolio of products serves all orthopedic applications Two-tier technology platform in orthobiologicals: Allograft – donor tissue Xeno

  15. Slide 15: Who We Are

    Slide 15: Who We Are

    WHO WE ARE We are Biologics for Orthopedic Tissue Repair; We are positioned in all major orthopedic markets Oral/ RTI Trauma Maxillofacial Reconstructive/ Sports Revision Medicine Surgery Spine $1.5 Billion Orthobiologics Market $25 Billion Orthopedic Device Industry

  16. Slide 16: Revenue Categories

    Slide 16: Revenue Categories

    REVENUE CATEGORIES (in thousands) 12 Months Ended 12 Months Ended % December 31, 2007 December 31, 2006 Inc/Dec SPINE $41.06 $35.09 17% SPORTS MEDICINE 27.69 14.96 85% BONE GRAFT SUBSTITUTES 17.01 13.50 26% GENERAL ORTHOPEDICS 1.00 .97 3% TOTAL CORE BUSINESS 86.76 64.53 34% CARDIOVASCULAR (exiting)

  17. Slide 17: Who We Are

    Slide 17: Who We Are

    WHO WE ARE Biologics Product Landscape – Industry Wide RTI is present in 75% of the biologics market Stem Cell, 1% Platelet Concentration, 2% Hyaluranic Bone Graft Injections, 22% Substitutes: 56% Sports Med Cartilage/Ligament Repair: 2% Machined/Tooled (excluding Autograft) Spine: 17%

  18. Slide 18: Where We Are

    Slide 18: Where We Are

    WHERE WE ARE Our Biologics Competitive landscape Bone Graft Substitutes* Growth factors: Protein based Platelet derived Sports Medicine* Allograft tissue (Cartilage/Ligament Repair) Biomaterials: Allograft tissue Hydroxyapatites Ceramic Autologous cultured Calcium phosphates chondrocytes Bone cement

  19. Slide 19: What Makes Us Different?

    Slide 19: What Makes Us Different?

    WHAT MAKES US DIFFERENT? BioCleanse ® differentiates our platform; Proprietary, patented, FDA reviewed and noted in peer-reviewed journal The New England Journal of Medicine - June 17, 2004 Maintain BIOCLEANSE®: Over Half Million Clinical Utility Scientifically Sterilized of Implant Undisputed, Allo

  20. Slide 20: What We've Been Doing

    Slide 20: What We've Been Doing

    WHAT WE’VE BEEN DOING Favorable execution of seven key agreements; provides further visibility and predictability Tutogen Agreement Nov 2006 Move to Non- Exclusive with Medtronic Orthofix/Blackstone Sep 2006 Spine Agreement Dec 2006 st 1 new spine partner in 9 years 2006:Prepared for New Business Mo

  21. Slide 21: Where We Are

    Slide 21: Where We Are

    WHERE WE ARE Better Business Model; predictability, sustainability & profitability Extremely Effective Diversified Group of Direct Sales in Distribution Partners Sports Medicine -Better pricing -High revenue/margin per unit -Better visibility -85% 2007 Y/Y growth -Increased utilization -96% Q4:07 gr

  22. Slide 22: Where We're Going: Sports Med

    Slide 22: Where We're Going: Sports Med

    WHERE WE’RE GOING: SPORTS MED Sports Medicine; positive trends; significant growth opportunity $ in millions $10.00 +96% $9.00 $8.00 +90% $7.00 +80.5% $6.00 +69% 2005 $5.00 2006 2007 $4.00 $3.00 $2.00 $1.00 $0.00 Qtr 1 Qtr 2 Qtr 3 Qtr 4 We have full control over sports medicine distribution Direct s

  23. Slide 23: Where We're Going: Sports Med

    Slide 23: Where We're Going: Sports Med

    WHERE WE’RE GOING: SPORTS MED Sports Medicine; We are addressing an unmet clinical need Segment (in $ millions) 2006 2007E 2008E 2009E 2010E CAGR Autograft $460 $481 $503 $525 $549 5% Allograft: $126 $139 $153 $168 $184 10% Bone Tendon Bone (BTB) $65 $72 $79 $87 $96 10% Soft Tissue implants $61 $67

  24. Slide 24: Where We're Going: BGS

    Slide 24: Where We're Going: BGS

    WHERE WE’RE GOING: BGS Bone Graft Substitutes; This is RTI turf; Take back share $ in millions Product Market 2006 Market 2007E In store for 2008 Introduce new one- DBM step paste to $205 $221 (RTI) address demand; expand distribution Synthetics $127 $143 Surgeons continue to be mixed BMP continues

  25. Slide 25: Recent Activities: BGS

    Slide 25: Recent Activities: BGS

    RECENT ACTIVITIES: BGS Zimmer Agreement – May 2007 Exclusive 10-year distribution agreement; $5 million in exclusivity payments New allograft bone paste; next generation, one-step delivery system - Flowable and moldable formulations derived solely from human tissue - Offers surgeons better performan

  26. Slide 26: Where We're Going: Xenograft

    Slide 26: Where We're Going: Xenograft

    WHERE WE’RE GOING: XENOGRAFT Xenograft; Facilitates steady growth in tissue market $2.3 billion market for biologics Biologics are preferred in the surgical community – patients are following; large ortho companies are positioning Limited supply of donor tissue limits allograft’s market opportunity

  27. Slide 27: Where We're Going: Xenograft

    Slide 27: Where We're Going: Xenograft

    WHERE WE’RE GOING: XENOGRAFT Be the leader in Xenograft; BioCleanse ® adds clinical benefit Image slices of a CT scan of one patient’s knee at seven month follow-up examination. The femoral interference screw is visible in the right-hand image. Research indicates the Sterling®Interference Screw comb

  28. Slide 28: What We've Been Doing: Xenograft

    Slide 28: What We've Been Doing: Xenograft

    WHAT WE’VE BEEN DOING: XENOGRAFT Xenograft; Wright Medical validates xeno opportunity Agreement to develop advanced xenograft implants for use in foot and ankle surgeries with Wright Medical – Feb. 12, 2007 New implants marketed by Wright under the CANCELLO-PURE™ brand A multi-purpose wedge version

  29. Slide 29: Investment Summary

    Slide 29: Investment Summary

    INVESTMENT SUMMARY Positive changes; Excellent outlook New business model gives us opportunity to leverage our technology & grow our business – recent results illustrate execution We are in the most dynamic segment of the $25 billion orthopedic device industry Merger positions us in worldwide biolog

  30. Slide 30: 2. Regeneration

    Slide 30: 2. Regeneration

    2. Regeneration

Source: SEC EDGAR · 425 filed Feb 19, 2008

More decks from RTI Surgical Holdings Inc